Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3649)
All Articles published online
|
Mar 14, 2005 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Schumacher G, Oidtmann M, Rueggeberg A, Jacob D, Jonas S, Langrehr JM, Neuhaus R, Bahra M, Neuhaus P. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol 2005; 11(10): 1420-1425 [PMID: 15770715 DOI: 10.3748/wjg.v11.i10.1420] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v11/i10/1420.htm |
| Number | Citing Articles |
| 1 |
Michael A. Zimmerman, Andrew M. Cameron, R. Mark Ghobrial. Liver Transplantation. 2009; : 103 doi: 10.1007/978-1-60327-028-1_6
|
| 2 |
Anantha K. Nuthalapati, Steven I. Hanish, Paul J. Thuluvath. Disease Recurrence After Liver Transplantation. 2016; : 153 doi: 10.1007/978-1-4939-2947-4_11
|
| 3 |
Marta Guerrero-Misas, Manuel Rodríguez-Perálvarez, Manuel De la Mata. Strategies to improve outcome of patients with hepatocellular carcinoma receiving a liver transplantation. World Journal of Hepatology 2015; 7(4): 649-661 doi: 10.4254/wjh.v7.i4.649
|
| 4 |
Angel Rubín Suárez, Itxarone Bilbao Aguirre, Javier Fernández-Castroagudin, José Antonio Pons Miñano, Magdalena Salcedo Plaza, Evaristo Varo Pérez, Martín Prieto Castillo. Recommendations of everolimus use in liver transplant. Gastroenterología y Hepatología (English Edition) 2017; 40(9): 629 doi: 10.1016/j.gastre.2017.10.006
|
| 5 |
Julio Pascual, Ioannis N. Boletis, Josep M. Campistol. Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions. Transplantation Reviews 2006; 20(1): 1 doi: 10.1016/j.trre.2005.10.005
|
| 6 |
M. Heuer, T. Benkö, V.R. Cicinnati, G.M. Kaiser, G.C. Sotiropoulos, H.A. Baba, J.W. Treckmann, C.E. Broelsch, A. Paul. Effect of Low-Dose Rapamycin on Tumor Growth in Two Human Hepatocellular Cancer Cell Lines. Transplantation Proceedings 2009; 41(1): 359 doi: 10.1016/j.transproceed.2008.10.090
|
| 7 |
A.O. Ferreiro, M.A. Vazquez-Millán, F.S. López, M.G. Gutiérrez, S.P. Diaz, M.J.L. Patiño. Everolimus-Based Immunosuppression in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Liver Transplantation: A Case Series. Transplantation Proceedings 2014; 46(10): 3496 doi: 10.1016/j.transproceed.2014.08.045
|
| 8 |
Jenny Abrahamsson, Malin Sternby Eilard, Magnus Rizell, William Bennett, Fredrik Åberg. Reduced calcineurin inhibitor exposure with antibody induction and recurrent hepatocellular carcinoma after liver transplantation. Scandinavian Journal of Gastroenterology 2022; 57(3): 325 doi: 10.1080/00365521.2021.2010799
|
| 9 |
Safak Gül-Klein, Paulina Schmitz, Wenzel Schöning, Robert Öllinger, Georg Lurje, Sven Jonas, Deniz Uluk, Uwe Pelzer, Frank Tacke, Moritz Schmelzle, Johann Pratschke, Ramin Raul Ossami Saidy, Dennis Eurich. The Role of Immunosuppression for Recurrent Cholangiocellular Carcinoma after Liver Transplantation. Cancers 2022; 14(12): 2890 doi: 10.3390/cancers14122890
|
| 10 |
Niloufar Saber-Moghaddam, Homa Nomani, Amirhossein Sahebkar, Thomas P. Johnston, Amir Hooshang Mohammadpour. The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following heart transplantation. International Immunopharmacology 2019; 69: 150 doi: 10.1016/j.intimp.2019.01.035
|
| 11 |
Maren Weischer, Martin Röcken, Mark Berneburg. Calcineurin inhibitors and rapamycin: cancer protection or promotion?. Experimental Dermatology 2007; 16(5): 385 doi: 10.1111/j.1600-0625.2007.00555.x
|
| 12 |
Annika Bundscherer, Christian Hafner. Cancer Microenvironment and Therapeutic Implications. 2009; : 221 doi: 10.1007/978-1-4020-9576-4_12
|
| 13 |
Qianying Lao, Xuanyu Wu, Xinxin Zheng, Jinwei Hu, Siqi Huang, Danying Li, Yao Du, Na Yang, Huaijun Zhu. Effect of Tacrolimus Time in Therapeutic Range on Postoperative Recurrence in Patients Undergoing Liver Transplantation for Liver Cancer. Therapeutic Drug Monitoring 2024; 46(1): 42 doi: 10.1097/FTD.0000000000001119
|
| 14 |
J.J Guiteau, R.T Cotton, W.K Washburn, A. Harper, C.A O’Mahony, A. Sebastian, S. Cheng, G. Klintmalm, M. Ghobrial, G. Halff, L. Mieles, J. Goss. An Early Regional Experience with Expansion of Milan Criteria for Liver Transplant Recipients. American Journal of Transplantation 2010; 10(9): 2092 doi: 10.1111/j.1600-6143.2010.03222.x
|
| 15 |
Alex Gutierrez-Dalmau, Josep M Campistol. Immunosuppressive Therapy and Malignancy in Organ Transplant Recipients. Drugs 2007; 67(8): 1167 doi: 10.2165/00003495-200767080-00006
|
| 16 |
Masaki Kaibori, Nobuaki Shikata, Tatsuma Sakaguchi, Morihiko Ishizaki, Kosuke Matsui, Hiroya Iida, Yoshito Tanaka, Hirokazu Miki, Richi Nakatake, Tadayoshi Okumura, Katsuji Tokuhara, Kentaro Inoue, Jouji Wada, Michio Oda, Mikio Nishizawa, Masanori Kon. Influence of Rictor and Raptor Expression of mTOR Signaling on Long-Term Outcomes of Patients with Hepatocellular Carcinoma. Digestive Diseases and Sciences 2015; 60(4): 919 doi: 10.1007/s10620-014-3417-7
|
| 17 |
K. V. Menon, A. R. Hakeem, N. D. Heaton. Meta‐analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics 2013; 37(4): 411 doi: 10.1111/apt.12185
|
| 18 |
Shi-lei Xu, Ying-cai Zhang, Guo-ying Wang, Qin Yang, Bo Liu, Jian Zhang, Hua Li, Gen-shu Wang, Yang Yang, Gui-hua Chen. Survival analysis of sirolimus-based immunosuppression in liver transplantation in patients with hepatocellular carcinoma. Clinics and Research in Hepatology and Gastroenterology 2016; 40(6): 674 doi: 10.1016/j.clinre.2016.03.006
|
| 19 |
Jeffrey Campsen, Michael A Zimmerman, James F Trotter, Michael Wachs, Thomas Bak, Susan Mandell, Igal Kam. Sirolimus and liver transplantation: clinical implications for hepatocellular carcinoma. Expert Opinion on Pharmacotherapy 2007; 8(9): 1275 doi: 10.1517/14656566.8.9.1275
|
| 20 |
Xiao Cui, Xiao-Ping Geng, Da-Chen Zhou, Ming-Hao Yang, Hui Hou. Advances in liver transplantation for unresectable colon cancer liver metastasis. World Journal of Gastrointestinal Surgery 2021; 13(12): 1615-1627 doi: 10.4240/wjgs.v13.i12.1615
Abstract(309) |
Core Tip(357) |
Full Article(HTML)(2084)
|
Full Article (PDF)-894K(363)
|
Full Article (Word)-198K(113)
|
Audio-483K(2)
|
Peer-Review Report-223K(81)
|
Answering Reviewers-89K(91)
|
Times Cited (0)
|
Total Visits (5403)
|
Open
|
| 21 |
Augusto Villanueva, Derek Y. Chiang, Pippa Newell, Judit Peix, Swan Thung, Clara Alsinet, Victoria Tovar, Sasan Roayaie, Beatriz Minguez, Manel Sole, Carlo Battiston, Stijn van Laarhoven, Maria I. Fiel, Analisa Di Feo, Yujin Hoshida, Steven Yea, Sara Toffanin, Alex Ramos, John A. Martignetti, Vincenzo Mazzaferro, Jordi Bruix, Samuel Waxman, Myron Schwartz, Matthew Meyerson, Scott L. Friedman, Josep M. Llovet. Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma. Gastroenterology 2008; 135(6): 1972 doi: 10.1053/j.gastro.2008.08.008
|
| 22 |
Laura M. Kulik, Mary F. Mulcahy, Reed A. Omary, Riad Salem. Emerging Approaches in Hepatocellular Carcinoma. Journal of Clinical Gastroenterology 2007; 41(9): 839 doi: 10.1097/MCG.0b013e318060ac52
|
| 23 |
Berik Rovgaliyev, Ming Yuan Tan, Kwang-Woong Lee, Seung Cheol Oh, Min Young Park, Sooin Seo, Hyo-Sun Choi, Suk Kyun Hong, Jae-Hyung Cho, Jeong-Moo Lee, Nam-Joon Yi, Kyung-Suk Suh. Sirolimus Attenuates Calcineurin Inhibitor-Induced Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma. Transplantation Proceedings 2022; 54(7): 2025 doi: 10.1016/j.transproceed.2022.04.027
|
| 24 |
See Ching Chan, Sheung Tat Fan. Historical perspective of living donor liver transplantation. World Journal of Gastroenterology 2008; 14(1): 15-21 doi: 10.3748/wjg.14.15
|
| 25 |
Sarah Jane Commander, Brian Shaw, Laura Washburn, Dor Yoeli, Abbas Rana, John A. Goss. A long‐term experience with expansion of Milan criteria for liver transplant recipients. Clinical Transplantation 2018; 32(6) doi: 10.1111/ctr.13254
|
| 26 |
Elena Navarro-Villarán, José Tinoco, Granada Jiménez, Sheila Pereira, Jize Wang, Sara Aliseda, María A. Rodríguez-Hernández, Raúl González, Luís M. Marín-Gómez, Miguel A. Gómez-Bravo, Francisco J. Padillo, José M. Álamo-Martínez, Jordi Muntané, Matias A Avila. Differential Antitumoral Properties and Renal-Associated Tissue Damage Induced by Tacrolimus and Mammalian Target of Rapamycin Inhibitors in Hepatocarcinoma: In Vitro and In Vivo Studies. PLOS ONE 2016; 11(8): e0160979 doi: 10.1371/journal.pone.0160979
|
| 27 |
Sharma Love, Malik A. Mudasir, Subhash C. Bhardwaj, Gurdarshan Singh, Sheikh A. Tasduq. Long-term administration of tacrolimus and everolimus prevents high cholesterol-high fructose-induced steatosis in C57BL/6J mice by inhibiting de-novo lipogenesis. Oncotarget 2017; 8(69): 113403 doi: 10.18632/oncotarget.15194
|
| 28 |
Tulio EF Pfiffer, Daniel Seehofer, Annett Nicolaou, Ruth Neuhaus, Hanno Riess, Ralf U Trappe. Recurrent hepatocellular carcinoma in liver transplant recipients: Parameters affecting time to recurrence, treatment options and survival in the sorafenib era. Tumori Journal 2011; 97(4): 436 doi: 10.1177/030089161109700404
|
| 29 |
Manuel Rodríguez-Perálvarez, Marta Guerrero, Lydia Barrera, Gustavo Ferrín, Jose M. Álamo, María D. Ayllón, Gonzalo Suarez Artacho, José L. Montero, Javier Briceño, Carmen Bernal, Javier Padillo, Luis M. Marín-Gómez, Juan M. Pascasio, Antonio Poyato, Miguel A. Gómez-Bravo, Manuel De la Mata. Impact of Early Initiated Everolimus on the Recurrence of Hepatocellular Carcinoma After Liver Transplantation. Transplantation 2018; 102(12): 2056 doi: 10.1097/TP.0000000000002270
|
| 30 |
Linda S Steelman, Kristin M Stadelman, William H Chappell, Stefan Horn, Jörg Bäsecke, Melchiorre Cervello, Ferdinando Nicoletti, Massimo Libra, Franca Stivala, Alberto M Martelli, James A McCubrey. Akt as a therapeutic target in cancer. Expert Opinion on Therapeutic Targets 2008; 12(9): 1139 doi: 10.1517/14728222.12.9.1139
|
| 31 |
Srinath Chinnakotla, Gary L. Davis, Sugam Vasani, Peter Kim, Koji Tomiyama, Edmund Sanchez, Nicholas Onaca, Robert Goldstein, Marlon Levy, Göran B. Klintmalm. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transplantation 2009; 15(12): 1834 doi: 10.1002/lt.21953
|
| 32 |
Lewis R Roberts, Gregory J Gores. Emerging drugs for hepatocellular carcinoma. Expert Opinion on Emerging Drugs 2006; 11(3): 469 doi: 10.1517/14728214.11.3.469
|
| 33 |
Viraj J. Jasinghe, Zhigang Xie, Jianbiao Zhou, Jiaying Khng, Lai-Fong Poon, Palaniyandi Senthilnathan, Keith B. Glaser, Daniel H. Albert, Steven K. Davidsen, Chien-Shing Chen. ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft. Journal of Hepatology 2008; 49(6): 985 doi: 10.1016/j.jhep.2008.08.010
|
| 34 |
Christian Toso, Glenda A. Meeberg, David L. Bigam, Jose Oberholzer, A M. James Shapiro, Klaus Gutfreund, Mang M. Ma, Andrew L. Mason, Winnie W. S. Wong, Vincent G. Bain, Norman M. Kneteman. De Novo Sirolimus-Based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma: Long-Term Outcomes and Side Effects. Transplantation 2007; 83(9): 1162 doi: 10.1097/01.tp.0000262607.95372.e0
|
| 35 |
Mamatha Bhat, Nahum Sonenberg, Gregory J. Gores. The mTOR pathway in hepatic malignancies. Hepatology 2013; 58(2): 810 doi: 10.1002/hep.26323
|
| 36 |
F. Panaro, T. Piardi, F. Gheza, B. Ellero, M. Audet, M. Cag, J. Cinqualbre, P. Wolf. Causes of Sirolimus Discontinuation in 97 Liver Transplant Recipients. Transplantation Proceedings 2011; 43(4): 1128 doi: 10.1016/j.transproceed.2011.01.143
|
| 37 |
Yao-Ming Wu, Brigid Joseph, Sanjeev Gupta. Immunosuppression using the mTOR inhibition mechanism affects replacement of rat liver with transplanted cells. Hepatology 2006; 44(2): 410 doi: 10.1002/hep.21277
|
| 38 |
Magnus Rizell, Mats Andersson, Christian Cahlin, Larsolof Hafström, Michael Olausson, Per Lindnér. Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. International Journal of Clinical Oncology 2008; 13(1): 66 doi: 10.1007/s10147-007-0733-3
|
| 39 |
Wolfgang Sieghart, Thorsten Fuereder, Katharina Schmid, Daniel Cejka, Johannes Werzowa, Fritz Wrba, Xiaowei Wang, Diego Gruber, Susanne Rasoul-Rockenschaub, Markus Peck-Radosavljevic, Volker Wacheck. Mammalian Target of Rapamycin Pathway Activity in Hepatocellular Carcinomas of Patients Undergoing Liver Transplantation. Transplantation 2007; 83(4): 425 doi: 10.1097/01.tp.0000252780.42104.95
|
| 40 |
Yasumasa Shirouzu, Eduard Ryschich, Olga Salnikova, Vachtang Kerkadze, Jan Schmidt, Guido Engelmann. Rapamycin Inhibits Proliferation and Migration of Hepatoma Cells In Vitro. Journal of Surgical Research 2010; 159(2): 705 doi: 10.1016/j.jss.2008.07.035
|
| 41 |
Ali Zarrinpar, Fady Kaldas, Ronald W Busuttil. Liver transplantation for hepatocellular carcinoma: an update. Hepatobiliary & Pancreatic Diseases International 2011; 10(3): 234 doi: 10.1016/S1499-3872(11)60039-8
|
| 42 |
Gerhard Treiber. mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Review of Anticancer Therapy 2009; 9(2): 247 doi: 10.1586/14737140.9.2.247
|
| 43 |
Christian Toso, Shaheed Merani, David L. Bigam, A.M. James Shapiro, Norman M. Kneteman. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010; 51(4): 1237 doi: 10.1002/hep.23437
|
| 44 |
A. Kornberg, B. Küpper, A. Tannapfel, K. Thrum, J. Wilberg, E. Bärthel, U. Settmacher. Adjuvant conversion to sirolimus in liver transplant patients with recurrent hepatocellular carcinoma – preliminary results. Transplant International 2007; 0(0): 071012050037002 doi: 10.1111/j.1432-2277.2007.00567.x
|
| 45 |
Augusto Villanueva, Clara Alsinet, Josep M. Llovet. Malignant Liver Tumors. 2010; : 368 doi: 10.1002/9781444317053.ch31
|
| 46 |
Paulo H. C. Diniz, Serena D. C. Silva, Paula V. T. Vidigal, Marcelo A. P. Xavier, Cristiano X. Lima, Luciana C. Faria, Teresa C. A. Ferrari, Liren Qian. Expression of MAPK and PI3K/AKT/mTOR Proteins according to the Chronic Liver Disease Etiology in Hepatocellular Carcinoma. Journal of Oncology 2020; 2020: 1 doi: 10.1155/2020/4609360
|
| 47 |
|
| 48 |
T. Decaens, C. Duvoux. Carcinome hépatocellulaire et transplantation hépatique : rôle futur des inhibiteurs de la mTOR. Gastroentérologie Clinique et Biologique 2009; 33: S257 doi: 10.1016/S0399-8320(09)73163-X
|
| 49 |
Jérôme Dumortier, Sebastien Dharancy, Yvon Calmus, Christophe Duvoux, François Durand, Ephrem Salamé, Faouzi Saliba. Use of everolimus in liver transplantation: The French experience. Transplantation Reviews 2016; 30(3): 161 doi: 10.1016/j.trre.2015.12.003
|
| 50 |
Manuel Rodríguez-Perálvarez, Manuel De la Mata, Andrew K. Burroughs. Liver transplantation. Current Opinion in Organ Transplantation 2014; 19(3): 253 doi: 10.1097/MOT.0000000000000069
|
| 51 |
Kan Chen, Kwan Man, Herold J. Metselaar, Harry L. A. Janssen, Maikel P. Peppelenbosch, Qiuwei Pan. Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation. Liver Transplantation 2014; 20(3): 261 doi: 10.1002/lt.23806
|
| 52 |
Daniel Hoffman, Neil Mehta. Recurrence of hepatocellular carcinoma following liver transplantation. Expert Review of Gastroenterology & Hepatology 2021; 15(1): 91 doi: 10.1080/17474124.2021.1823213
|
| 53 |
Giuseppe Marrone, Maria Sandrina Leone, Marco Biolato, Antonio Liguori, Giuseppe Bianco, Gabriele Spoletini, Antonio Gasbarrini, Luca Miele, Maurizio Pompili. Therapeutic Approach to Post-Transplant Recurrence of Hepatocellular Carcinoma: Certainties and Open Issues. Cancers 2023; 15(23): 5593 doi: 10.3390/cancers15235593
|
| 54 |
E.L.D. de Mare-Bredemeijer, H.J. Metselaar. Optimization of the use of Calcineurin inhibitors in liver transplantation. Best Practice & Research Clinical Gastroenterology 2012; 26(1): 85 doi: 10.1016/j.bpg.2012.01.017
|
| 55 |
Manuel Rodríguez-Perálvarez, Emmanuel Tsochatzis, María Carmen Naveas, Giulia Pieri, Carmen García-Caparrós, James O’Beirne, Antonio Poyato-González, Gustavo Ferrín-Sánchez, Jose Luis Montero-Álvarez, David Patch, Douglas Thorburn, Javier Briceño, Manuel De la Mata, Andrew Kenneth Burroughs. Reduced exposure to calcineurin inhibitors early after liver transplantation prevents recurrence of hepatocellular carcinoma. Journal of Hepatology 2013; 59(6): 1193 doi: 10.1016/j.jhep.2013.07.012
|
| 56 |
Rahul Kakodkar, A. S. Soin. Liver Transplantation for HCC: A Review. Indian Journal of Surgery 2012; 74(1): 100 doi: 10.1007/s12262-011-0387-2
|
| 57 |
Marta Guerrero, Gustavo Ferrín, Manuel Rodríguez-Perálvarez, Sandra González-Rubio, Marina Sánchez-Frías, Víctor Amado, Juan Pozo, Antonio Poyato, Rubén Ciria, María Ayllón, Pilar Barrera, José Montero, Manuel de la Mata. mTOR Expression in Liver Transplant Candidates with Hepatocellular Carcinoma: Impact on Histological Features and Tumour Recurrence. International Journal of Molecular Sciences 2019; 20(2): 336 doi: 10.3390/ijms20020336
|
| 58 |
Filippo Pelizzaro, Martina Gambato, Enrico Gringeri, Alessandro Vitale, Umberto Cillo, Fabio Farinati, Patrizia Burra, Francesco Paolo Russo. Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Cancers 2021; 13(19): 4882 doi: 10.3390/cancers13194882
|
| 59 |
Christian Toso, Seema Patel, Sonal Asthana, Toshiyasu Kawahara, Safwat Girgis, Norman N. Kneteman, A.M. James Shapiro, David L. Bigam. The impact of sirolimus on hepatocyte proliferation after living donor liver transplantation. Clinical Transplantation 2010; 24(5): 695 doi: 10.1111/j.1399-0012.2009.01159.x
|
| 60 |
Christopher J.E. Watson, J. Andrew Bradley. Sirolimus and everolimus: inhibitors of mammalian target of rapamycin in liver transplantation. Transplantation Reviews 2006; 20(2): 104 doi: 10.1016/j.trre.2006.06.001
|
| 61 |
Truman Mark Earl, William C. Chapman. Multidisciplinary Treatment of Hepatocellular Carcinoma. Recent Results in Cancer Research 2013; 190: 145 doi: 10.1007/978-3-642-16037-0_10
|
| 62 |
Sabine J. Presser, Guido Schumacher, Ruth Neuhaus, Peter Thuss-Patience, Jens Stieler, Peter Neuhaus. De novo esophageal neoplasia after liver transplantation. Liver Transplantation 2007; 13(3): 443 doi: 10.1002/lt.21058
|
| 63 |
Angel Rubín Suárez, Itxarone Bilbao Aguirre, Javier Fernández-Castroagudin, José Antonio Pons Miñano, Magdalena Salcedo Plaza, Evaristo Varo Pérez, Martín Prieto Castillo. Recomendaciones de uso de everolimus en el trasplante hepático. Gastroenterología y Hepatología 2017; 40(9): 629 doi: 10.1016/j.gastrohep.2017.05.008
|
| 64 |
Giulia Castelli, Patrizia Burra, Anna Giacomin, Alessandro Vitale, Marco Senzolo, Umberto Cillo, Fabio Farinati. Sorafenib use in the transplant setting. Liver Transplantation 2014; 20(9): 1021 doi: 10.1002/lt.23911
|
| 65 |
T Ogawa, H Tashiro, Y Miyata, Y Ushitora, Y Fudaba, T Kobayashi, K Arihiro, M Okajima, T Asahara. Rho-Associated Kinase Inhibitor Reduces Tumor Recurrence After Liver Transplantation in a Rat Hepatoma Model. American Journal of Transplantation 2007; 7(2): 347 doi: 10.1111/j.1600-6143.2006.01647.x
|
| 66 |
Zhi-Hua Zhang, Li Xin Li, Ping Li, Shao-Cheng Lv, Bing Pan, Qiang He. Sirolimus in Liver Transplant Recipients with Hepatocellular Carcinoma: An Updated Meta-Analysis. Journal of Investigative Surgery 2019; 32(7): 632 doi: 10.1080/08941939.2018.1447053
|
| 67 |
Hans J. Schlitt, Françoise Mornex, Abraham Shaked, James F. Trotter. Immunosuppression and hepatocellular carcinoma. Liver Transplantation 2011; 17(S2): S159 doi: 10.1002/lt.22318
|
| 68 |
Jian Zhou, Jia Fan, Zheng Wang, Zhi-Quan Wu, Shuang-Jian Qiu, Xiao-Wu Huang, Yao Yu, Jian Sun, Yong-Sheng Xiao, Yi-Feng He, Yu-Qi Wang, Zhao-You Tang. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience. World Journal of Gastroenterology 2006; 12(19): 3114-3118 doi: 10.3748/wjg.v12.i19.3114
|
| 69 |
Elizabeth C. Verna, Yuval A. Patel, Avin Aggarwal, Archita P. Desai, Catherine Frenette, Anjana A. Pillai, Reena Salgia, Anil Seetharam, Pratima Sharma, Courtney Sherman, Georgios Tsoulfas, Francis Y. Yao. Liver transplantation for hepatocellular carcinoma: Management after the transplant. American Journal of Transplantation 2020; 20(2): 333 doi: 10.1111/ajt.15697
|
| 70 |
Isabelle Morard, Jérôme Dumortier, Laurent Spahr, Antoine Hadengue, Pietro Majno, Philippe Morel, Gilles Mentha, Emiliano Giostra. Conversion to sirolimus-based immunosuppression in maintenance liver transplantation patients. Liver Transplantation 2007; 13(5): 658 doi: 10.1002/lt.21116
|